\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

obligations may continue. See Instruction 1(b).		Se ob		orm 5
--	--	----------	--	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* <u>MCINERNEY TIMOTHY</u>			on [*]	2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP]		tionship of Reporting Perso all applicable) Director	on(s) to Issuer 10% Owner	
		(First) (Middle) NT BIOCAPITAL		3. Date of Earliest Transaction (Month/Day/Year) 02/23/2007		Officer (give title below)	Other (specify below)	
		FLOOR	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	ividual or Joint/Group Filing (Check Applicable			
	(Street)	NTN /	10010			Form filed by One Repor	ting Person	
	NEW YORK	NY	10019			Form filed by More than Person	One Reporting	
	(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date	2A. Deemed Execution Date,	3. 4. Securities Acquired (A) o Transaction Disposed Of (D) (Instr. 3, 4 a			(A) or	5. Amount of Securities	6. Ownership Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)		· · · · ·			Beneficially Owned Following Reported		(D) or Indirect (I) (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock, \$.001 par value	03/15/2007		Р		4,000	A	\$ 5	63,205	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration D (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants to Purchase Common Stock	\$4.75							09/13/2005	05/31/2012	Common Stock, \$.001 par value	20,767		20,767	D	
Director Stock Option (right to buy)	\$4.31							(1)	07/20/2015	Common Stock, \$.001 par value	15,029		15,029	D	
Director Stock Option (right to buy)	\$5.01							04/26/2006	04/26/2016	Common Stock	15,000		15,000	D	
Warrants to Purchase Common Stock	\$5.09							05/03/2006	05/03/2013	Common Stock, \$.001 par value	80,737		80,737	D	
Director Stock Option (right to buy)	\$6.49							(2)	12/13/2016	Common Stock	15,000		15,000	D	
Warrant	\$5.75	02/23/2007		J ⁽³⁾		35,739		02/23/2007	02/23/2012	Common Stock	35,739	\$0	35,739	D	

Explanation of Responses:

1. 7,515 shares vest on 7/20/06 and 7,514 shares vest on 7/20/07.

2. 5,000 shares vest on each of 12/13/07, 12/13/08 and 12/13/09.

3. Warrant issued as part of a private placement for services rendered.

<u>/s/ Timothy McInerney</u>

** Signature of Reporting Person

03/22/2007

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.